PT1660095E - Inibidores tricíclicos de parp - Google Patents
Inibidores tricíclicos de parp Download PDFInfo
- Publication number
- PT1660095E PT1660095E PT04743516T PT04743516T PT1660095E PT 1660095 E PT1660095 E PT 1660095E PT 04743516 T PT04743516 T PT 04743516T PT 04743516 T PT04743516 T PT 04743516T PT 1660095 E PT1660095 E PT 1660095E
- Authority
- PT
- Portugal
- Prior art keywords
- parp inhibitors
- tricyclic
- lactam
- relates
- tricyclic parp
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- -1 lactam indole derivatives Chemical class 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317466.1A GB0317466D0 (en) | 2003-07-25 | 2003-07-25 | Use |
| GB0408524A GB0408524D0 (en) | 2004-04-16 | 2004-04-16 | Use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1660095E true PT1660095E (pt) | 2010-04-19 |
Family
ID=34117642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04743516T PT1660095E (pt) | 2003-07-25 | 2004-07-23 | Inibidores tricíclicos de parp |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7351701B2 (pt) |
| EP (1) | EP1660095B1 (pt) |
| JP (2) | JP5466814B2 (pt) |
| KR (1) | KR101138471B1 (pt) |
| AT (1) | ATE454893T1 (pt) |
| AU (1) | AU2004261462B2 (pt) |
| BR (1) | BRPI0412899B1 (pt) |
| CA (1) | CA2533332C (pt) |
| CY (1) | CY1110335T1 (pt) |
| DE (1) | DE602004025123D1 (pt) |
| DK (1) | DK1660095T3 (pt) |
| ES (1) | ES2339663T3 (pt) |
| IL (1) | IL173336A (pt) |
| MX (1) | MXPA06000993A (pt) |
| NO (1) | NO334610B1 (pt) |
| NZ (1) | NZ544989A (pt) |
| PL (1) | PL1660095T3 (pt) |
| PT (1) | PT1660095E (pt) |
| RU (1) | RU2404183C2 (pt) |
| SI (1) | SI1660095T1 (pt) |
| WO (1) | WO2005012305A2 (pt) |
| ZA (1) | ZA200600679B (pt) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030020488A (ko) * | 2001-08-29 | 2003-03-10 | 강정훈 | 대나무 추출물을 유효성분으로 하는 화상치료용 조성물 |
| EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| NZ544989A (en) | 2003-07-25 | 2009-10-30 | Cancer Rec Tech Ltd | Tricyclic PARP inhibitors |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| BRPI0417056A (pt) * | 2003-12-01 | 2007-02-06 | Kudos Pharm Ltd | inibidores de reparo de dano no dna para tratamento de cáncer |
| MX2007003314A (es) * | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| MX2007002461A (es) * | 2004-09-22 | 2008-03-13 | Pfizer | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona. |
| EP1841771A4 (en) | 2005-01-19 | 2008-09-24 | Mgi Gp Inc | COMPOUNDS OF DIAZABENZO [DE] ANTHRACENE-3-ONE AND USE IN INHIBITION OF PARP |
| NZ587586A (en) | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| EP2061479A4 (en) | 2006-09-05 | 2010-08-04 | Bipar Sciences Inc | FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH |
| JP5439380B2 (ja) | 2007-10-03 | 2014-03-12 | エーザイ インク． | Ｐａｒｐ阻害化合物、組成物及び使用方法 |
| US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CA2705537A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CA2713156A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| GB0804755D0 (en) * | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| KR20120127495A (ko) | 2010-02-12 | 2012-11-21 | 화이자 인코포레이티드 | 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체 |
| DK2582847T3 (en) | 2010-06-18 | 2016-12-19 | Myriad Genetics Inc | METHODS AND MATERIALS TO ASSESS loss of heterozygosity |
| EP3109325B1 (en) | 2010-08-24 | 2018-12-26 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| EP2646428B1 (en) | 2010-12-02 | 2016-06-01 | Shanghai De Novo Pharmatech Co Ltd. | Heterocyclic derivatives, preparation processes and medical uses thereof |
| US20140051737A1 (en) * | 2011-05-10 | 2014-02-20 | Universite Laval | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
| CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| AU2012286542A1 (en) | 2011-07-22 | 2014-02-06 | Pacylex Pharmaceuticals Inc. | Synthetic lethality and the treatment of cancer |
| FI2794907T4 (fi) | 2011-12-21 | 2023-03-27 | Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi | |
| NZ628813A (en) | 2012-02-23 | 2015-10-30 | Univ Denmark Tech Dtu | Methods for predicting anti-cancer response |
| US11091808B2 (en) | 2012-06-07 | 2021-08-17 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| EP2892344A1 (de) * | 2012-09-05 | 2015-07-15 | Bayer CropScience AG | Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| US10308986B2 (en) | 2013-03-14 | 2019-06-04 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| US20140363521A1 (en) | 2013-04-05 | 2014-12-11 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| US11149316B2 (en) | 2013-12-09 | 2021-10-19 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| ES3039109T3 (en) | 2014-08-15 | 2025-10-17 | Myriad Genetics Inc | Methods and materials for assessing homologous recombination deficiency |
| KR102803917B1 (ko) | 2014-08-22 | 2025-05-07 | 파르마＆ 슈바이츠 게엠베하 | 루카파립의 고 용량 강도 정제 |
| KR20160116831A (ko) | 2015-03-31 | 2016-10-10 | (주)아모레퍼시픽 | 코지산 유도체를 유효성분으로 포함하는 장수 유전자 활성화용 조성물 |
| EP3325662B1 (en) | 2015-07-17 | 2023-08-30 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
| WO2017013237A1 (en) | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| AU2016340878A1 (en) * | 2015-10-19 | 2018-05-10 | Dana-Farber Cancer Institute, Inc. | Polymerase Q as a target in HR-deficient cancers |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| EP3377068B1 (en) | 2015-11-20 | 2025-03-26 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| WO2017173323A1 (en) | 2016-04-01 | 2017-10-05 | NOHMs Technologies, Inc. | Modified ionic liquids containing phosphorus |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| RU2019114863A (ru) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| US12121518B2 (en) | 2017-03-09 | 2024-10-22 | The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College | PARP-1 and methods of use thereof |
| WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| EP3615026B1 (en) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| EP4087005A1 (en) | 2017-07-17 | 2022-11-09 | Nohms Technologies, Inc. | Phosphorus-containing electrolytes |
| MX2020007060A (es) | 2018-01-05 | 2020-11-11 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. |
| RU2020130050A (ru) | 2018-02-15 | 2022-03-15 | Сэньхва Байосайенсиз, Инк. | Аналоги хинолонов и их соли, композиции и способ их применения |
| EP3765613A1 (en) | 2018-03-13 | 2021-01-20 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| CN113454080B (zh) | 2018-10-30 | 2025-10-28 | 修复治疗公司 | 化合物、药物组合物和制备化合物的方法以及其使用方法 |
| MX2022000450A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. |
| PH12022550039A1 (en) | 2019-07-10 | 2023-06-26 | Cybrexa 3 Inc | Peptide conjugates of cytotoxins as therapeutics |
| CN114072410B (zh) * | 2019-08-01 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 作为parp抑制剂吲哚并七元酰肟化合物 |
| US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CA3176206A1 (en) | 2020-04-28 | 2021-11-04 | Debnath Bhuniya | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| US20240199582A1 (en) | 2021-04-08 | 2024-06-20 | Rhizen Pharmaceuticals Ag | Inhibitors of poly(adp-ribose) polymerase |
| EP4141127B1 (en) | 2021-08-30 | 2024-10-09 | Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln | Method for assessing homologous recombination deficiency in ovarian cancer cells |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| AU2023279251A1 (en) | 2022-06-01 | 2024-12-05 | Glaxosmithkline Intellectual Property (No. 4) Ltd. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736534A (en) * | 1994-02-23 | 1998-04-07 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
| SK287338B6 (sk) | 1999-01-11 | 2010-07-07 | Agouron Pharmaceuticals, Inc. | Tricyklická zlúčenina, jej použitie a farmaceutická kompozícia s jej obsahom |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| US7449464B2 (en) * | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| NZ544989A (en) | 2003-07-25 | 2009-10-30 | Cancer Rec Tech Ltd | Tricyclic PARP inhibitors |
| BRPI0417056A (pt) * | 2003-12-01 | 2007-02-06 | Kudos Pharm Ltd | inibidores de reparo de dano no dna para tratamento de cáncer |
| MX2007003314A (es) | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
-
2004
- 2004-07-23 NZ NZ544989A patent/NZ544989A/en not_active IP Right Cessation
- 2004-07-23 CA CA2533332A patent/CA2533332C/en not_active Expired - Lifetime
- 2004-07-23 BR BRPI0412899-0A patent/BRPI0412899B1/pt not_active IP Right Cessation
- 2004-07-23 AT AT04743516T patent/ATE454893T1/de active
- 2004-07-23 PT PT04743516T patent/PT1660095E/pt unknown
- 2004-07-23 RU RU2006105652/04A patent/RU2404183C2/ru active
- 2004-07-23 US US10/898,653 patent/US7351701B2/en not_active Expired - Lifetime
- 2004-07-23 JP JP2006521648A patent/JP5466814B2/ja not_active Expired - Fee Related
- 2004-07-23 MX MXPA06000993A patent/MXPA06000993A/es active IP Right Grant
- 2004-07-23 AU AU2004261462A patent/AU2004261462B2/en not_active Expired
- 2004-07-23 KR KR1020067001725A patent/KR101138471B1/ko not_active Expired - Fee Related
- 2004-07-23 PL PL04743516T patent/PL1660095T3/pl unknown
- 2004-07-23 DE DE602004025123T patent/DE602004025123D1/de not_active Expired - Lifetime
- 2004-07-23 EP EP04743516A patent/EP1660095B1/en not_active Expired - Lifetime
- 2004-07-23 SI SI200431370T patent/SI1660095T1/sl unknown
- 2004-07-23 ES ES04743516T patent/ES2339663T3/es not_active Expired - Lifetime
- 2004-07-23 US US10/565,308 patent/US7531530B2/en not_active Expired - Lifetime
- 2004-07-23 WO PCT/GB2004/003183 patent/WO2005012305A2/en not_active Ceased
- 2004-07-23 DK DK04743516.9T patent/DK1660095T3/da active
-
2006
- 2006-01-24 IL IL173336A patent/IL173336A/en active IP Right Grant
- 2006-01-24 ZA ZA2006/00679A patent/ZA200600679B/en unknown
- 2006-02-24 NO NO20060928A patent/NO334610B1/no unknown
-
2010
- 2010-03-31 CY CY20101100309T patent/CY1110335T1/el unknown
-
2011
- 2011-11-29 JP JP2011260401A patent/JP5580280B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1660095T3 (pl) | Tricykliczne inhibitory PARP | |
| WO2002044183A3 (en) | Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors | |
| MY133311A (en) | Novel imidazopyridines as cyclin dependent kinase inhibitors | |
| HUP0500574A3 (en) | Acridone inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
| IL181700A0 (en) | Quinazoline derivatives and pharmaceutical compositions containing the same | |
| IL187382A0 (en) | Bicyclic derivatives as modulators of ion channels | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| SG145700A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| SG145695A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| MY122771A (en) | Heterocyclically substituted benzimidazoles, their preparation and use thereof | |
| MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
| HUP0501182A3 (en) | Aza spiro alkane derivatives as inhibitors of metallproteases and pharmaceutical compositions containing them | |
| ZA200706029B (en) | Tricyclic &-opioid domulators | |
| MXPA03008045A (es) | Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv. | |
| SI1641803T1 (sl) | Tienopirimidinski derivati kot inhibitorji kalijevih kanalov | |
| HUP0203288A3 (en) | Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use | |
| AU2003226724A8 (en) | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands | |
| HUP0203245A3 (en) | Imidazopyridine derivatives as phosphodiesterase vii inhibitors and pharmaceutical compositions containing them | |
| MY136840A (en) | Pyrazolopyridines as cyclin dependent kinase inhibitors | |
| EP1244452A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
| MXPA05012953A (es) | Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos. | |
| WO2002011732A8 (en) | Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists | |
| ZA201000581B (en) | 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| HUP0301173A3 (en) | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme |